ICU Equipment in California

ExThera Medical Corporation develops and commercializes the Seraph® 100 Microbind® Affinity Blood Filter, a single-use, extracorporeal blood filtration device designed to reduce pathogen levels in the bloodstream for patients with life-threatening bloodstream infections, sepsis, and related critical care conditions. The Seraph 100 employs proprietary microbead adsorption media with chemically-bonded modified heparin to selectively bind and remove pathogens—including bacteria, viruses, and endotoxins—from circulating blood while leaving the blood itself intact in the filter. The technology has been studied for COVID-19 treatment and is now advancing into clinical trials for broader infectious disease applications and oncology-related conditions through pipeline programs including ONCObind®. The company is advancing Phase I clinical trials (OSCAR I) for bloodstream infection management and exploring applications in pancreatic cancer treatment. ExThera's extracorporeal blood purification approach addresses a critical unmet need in intensive care settings where pathogenic load reduction can improve outcomes in sepsis, severe infections, and related hemodynamic compromise. The company maintains regulatory development pathways and publishes peer-reviewed clinical and preclinical data. Manufacturing and quality systems support single-use, sterile device production for hospital and critical care deployment.

Belun Technology designs and manufactures medical-grade wearable devices and AI-powered software platforms for sleep health monitoring, home sleep apnea testing, and remote patient vital signs monitoring. The company's core offerings include the Belun® Ring, an FDA 510(k)-cleared wearable device that performs home sleep apnea screening and monitors sleep health using clinically validated algorithms, and the Belun® remoVital system, a real-time remote vital signs monitoring solution comprising the Belun® Ring, Belun® COR (body temperature sensor), and a communication hub. The remoVital system measures blood oxygen saturation, pulse rate, and body temperature, with alert functionality designed to enable early detection of clinical deterioration and support timely medical intervention. Products target both consumers seeking self-managed wellness monitoring and healthcare professionals requiring scalable remote monitoring solutions for clinical accuracy and care quality improvement. The company emphasizes medical-grade accuracy, ease of use, and affordability. Belun holds FDA 510(k) clearance for its sleep monitoring and vital signs monitoring systems. The platform employs proprietary AI algorithms for predictive analytics and personalized care delivery. Markets served include home-based sleep apnea screening, remote patient monitoring in residential care facilities, and integrated telehealth/remote care workflows. The company has received strategic investment from IHH Healthcare and Gravity Capital Partners, indicating growth in global expansion and product development.

ClearFlow, Inc. manufactures specialized medical devices for cardiac surgery and cardiothoracic care. The company's primary product is PleuraFlow Active Chest Tube Clearance (ACT), a technology designed to prevent Retained Blood Syndrome and reduce postoperative complications in cardiac surgery patients. The PleuraFlow system actively clears blood and fluid from the thoracic cavity after surgery, demonstrating significant clinical benefits including 41% reduction in Retained Blood Syndrome, 17% reduction in postoperative atrial fibrillation, and 30% reduction in ICU length of stay when integrated into Enhanced Recovery After Surgery (ERAS) protocols. The company also offers ClearFix, a rigid sternal fixation system for stabilization and fixation of anterior chest wall fractures, including sternal fixation following sternotomy and sternal reconstructive procedures. ClearFlow's products are deployed in leading cardiac institutions and ICUs. The technology is supported by clinical evidence, including peer-reviewed publications demonstrating improved patient outcomes and resource utilization. The company serves cardiac surgeons, cardiothoracic surgical teams, and hospital ICU departments focused on reducing postoperative complications and improving recovery times in cardiac surgery populations.

Totex Manufacturing Inc. is a US-based designer and manufacturer of custom battery packs and charging systems serving medical, industrial, aerospace, and consumer markets since 1985 (35+ years of experience). The company provides comprehensive solutions from initial design through manufacturing, testing, and global logistics. In the medical sector, Totex supplies rechargeable batteries and chargers for portable diagnostic devices (ultrasound machines, blood pressure monitors, insulin pumps, portable monitors), portable medical equipment, and ICU/emergency devices requiring reliable power in demanding environments. The company manufactures to rigorous medical standards and maintains FDA registration. Core manufacturing capabilities include circuit design and PCB layout, fuel gauge and MCU firmware programming, in-house SMT assembly (7 fully automatic lines), plastic injection molding (27 machines), ultrasonic and spot welding, and automated cell sorting. Quality systems include ISO 9001, ISO 13485, and ISO 14001 certifications, with in-house UL2054 testing, Six Sigma training (1 master black belt, 2 black belts, 30+ green belts), and DPPMs typically <500 per year. Environmental testing capabilities in-house include temperature cycling, thermal shock, humidity, IP68 dust/water intrusion, vibration, drop, shock, and nail penetration testing. The company operates two manufacturing facilities (Torrance, California: 55,000 sq. ft.; Huizhou, China: 120,000 sq. ft.) with vertical integration enabling cost-effective and consistent production. Expertise spans all major cell chemistries: Li-Ion, LiFePO4, NiMH, Li-SOCl2. Logistics support includes ~98% on-time delivery, Kanban/VMI/consignment programs, and specialized handling of lithium-ion battery shipping regulations. Designs include autoclave and intrinsically safe ratings for medical applications.

AccuVein is a medical device manufacturer specializing in near-infrared (NIR) vein visualization technology for vascular access procedures. The company develops handheld vein finder devices that enable healthcare professionals to visualize peripheral veins, valves, and bifurcations not visible to the naked eye, improving peripheral IV catheter placement success rates and reducing procedure time and complications. AccuVein's primary products serve acute care settings (emergency departments, ICUs, general wards), non-acute care environments (outpatient clinics, home care), and aesthetic/cosmetic medicine practices. Clinical evidence supports the technology with 92% first-attempt success rates for IV placement, 78% reduction in procedure time, 45% decrease in escalation calls, and 39% reduction in patient pain. The company manufactures multiple generations of vein visualization devices, including the AV500, AV600 (fourth-generation model recently launched), and associated accessories such as the HF580 Powered Stand for hands-free mobile applications. AccuVein's devices are recommended by leading professional societies for pre-insertion vascular assessment and are positioned to improve clinical outcomes, operational efficiency, staff well-being, and healthcare equity by enabling successful venous access across diverse patient populations.

NeVap Inc manufactures airway management devices focused on infection prevention and critical care outcomes. The company's flagship product is the Aspire Subglottic Endotracheal Tube (ASSET), a subglottic suction breathing tube engineered with a tissue spacer and multiple drainage ports to prevent tissue blockage during suctioning. The ASSET is designed to reduce ventilator-associated pneumonia (VAP), post-operative pneumonia, and aspiration pneumonia incidence by enabling effective subglottic drainage in ICU, operating room, and emergency department settings. Clinical evidence demonstrates that subglottic drainage reduces mechanical ventilation duration, pneumonia incidence, antibiotic consumption, and mortality in long-term ventilated patients. The device is supported by recommendations from the CDC, AHRQ, ATS, SHEA, APIC, IDSA, and AACN. NeVap's leadership includes medical device executives and FDA compliance experts, with an advisory board composed of life sciences professionals. The company is positioned to serve hospitals and healthcare systems across the Bay Area and beyond, addressing a significant clinical need in airway management and infection prevention protocols.

AirICU Inc. manufactures and distributes aerosol drug delivery systems for acute care and intensive care unit (ICU) environments. The company's primary product line focuses on nebulization solutions for critical care applications. AirICU Max+ is a medical mesh nebulizer designed for hospital and acute care settings, delivering aerosolized medications to critically ill patients. The company positions itself as a provider of full-scenario nebulization support for critical care facilities. Products are designed for use in ventilated and non-ventilated patient populations in ICU environments. The company serves hospital acute care departments and critical care units. No specific FDA clearance, ISO, or regulatory certifications are mentioned on the fetched website content, though such approvals would be expected for ICU medical devices distributed in the US market.